Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...

Alnylam Pharmaceuticals (NASDAQ:ALNY), with a market capitalization of $35.4 billion, has emerged as a leading player in the RNA interference (RNAi) therapeutics space, with a particular focus on ...

The U.S. Navy has developed a directed-energy weapon that can intercept unmanned drones and possibly cruise missiles while ...

The Navy has shown off its jaw-dropping new laser weapon. The HELIOS system can be seen firing from a warship in an internal ...